Dr. Isaacs has received honoraria from Genentech/Roche, Celgene, AstraZeneca, and Pfizer; served in a consulting or advisory role for Pfizer, Caris Life Sciences, and Genentech/Roche; served on speakers' bureaus for Genentech, Celgene, Pfizer, and AstraZeneca; received research funding from Novartis, Pfizer, Genentech, and Tesaro; and has accepted travel, accommodations, and expenses provided by Caris Life Sciences. Drs. Liu and Selvam are employees of HealthCore, Inc., a wholly owned subsidiary of Anthem, Inc. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
See JNCCN.org for supplemental online content.
Romond EH, Perez EA, Bryant J. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673–1684.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659–1672.
Carlson RW, Anderson BO, Bensinger W. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2005. Accessed January 12, 2015. To view the most recent version of these guidelines, visit NCCN.org.
Carlson RW, Allred DC, Anderson BO. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2010. Accessed January 12, 2015. To view the most recent version of these guidelines, visit NCCN.org.
National Cancer Institute. Table 1.22 U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2009. Available at: https://seer.cancer.gov/archive/csr/1975_2009_pops09/results_single/sect_01_table.22_2pgs.pdf. Accessed August 18, 2016.
American Cancer Society. Breast Cancer Facts & Figures 2013-2014. Available at: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-042725.pdf. Accessed September 22, 2016.
Clarke CA, Keegan TH, Yang J. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst 2012;104:1094–1101.
O'Neill SC, Isaacs C, Chao C. Adoption of gene expression profiling for breast cancer in us oncology practice for women younger than 65 years. J Natl Compr Canc Netw 2015;13:1216–1224.
Gonzalez-Angulo AM, Litton JK, Broglio KR. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009;27:5700–5706.
Slamon DJ, Clark GM, Wong SG. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–182.
Vaz-Luis I, Lin NU, Keating NL. Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab. Breast Cancer Res Treat 2016;159:151–162.
Reeder-Hayes K, Peacock HS, Meng K. Disparities in use of human epidermal growth hormone receptor 2-targeted therapy for early-stage breast cancer. J Clin Oncol 2016;34:2003–2009.
Freedman RA, Hughes ME, Ottesen RA. Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network. Cancer 2013;119:839–846.
Tsai HT, Isaacs C, Fu AZ. Risk of cardiovascular adverse events from trastuzumab (Herceptin) in elderly persons with breast cancer: a population-based study. Breast Cancer Res Treat 2014;144:163–170.
Kurian AW, Thompson RN, Gaw AF. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol 2007;25:634–641.
Leung W, Kvizhinadze G, Nair N, Blakely T. Adjuvant trastuzumab in HER2-positive early breast cancer by age and hormone receptor status: a cost-utility analysis. PLoS Med 2016;13:e1002067.